SOURCE-LINKED STUDY SUMMARY
Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach.
Abstract summarizedQuality not appraised
- What was studied
- A lifetime disease model compared semaglutide plus diet and exercise with diet and exercise alone, estimating health outcomes and carbon emissions.
- Who / model studied
- The model used STEP and SELECT trial data for UK populations with overweight or obesity, including groups with complications or established cardiovascular disease. No new participant sample is described.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Estimated lifetime emissions fell 1.8% and 1.9% in two populations. In established cardiovascular disease, estimated survival rose 0.56 years, but emissions increased from 14,444 to 14,700 kilograms of carbon-dioxide equivalent. These are modelled projections.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1007/s40273-026-01659-4